Navigation Links
Considering Corticosteroid Nasal Sprays
Date:7/31/2013

MCLEAN, Va., July 31, 2013 /PRNewswire-USNewswire/ -- Today, leading nonprofit patient advocacy and education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) released results of a survey regarding patient use of intranasal corticosteroid sprays. Findings were shared during the Food and Drug Administration (FDA) Nonprescription Drug Advisory Committee meeting considering the switch of triamcinolone nasal spray from prescription to over-the-counter status.

"AANMA conducted a survey of more than 1,600 families and patients who use nasal corticosteroid sprays and found that they are prescribed to treat a complex set of symptoms for patients who often take an assortment of other medications," says Nancy Sander, president and founder of AANMA and a nationally recognized patient advocate. "This makes patient education a high priority for safe use. When medications are available over-the-counter, families tell us they assume it is safe to self-diagnose their conditions and pick and choose among medications."

Nine out of 10 said they prefer to rely on medical professionals to diagnose and manage their conditions. When asked if intranasal corticosteroid sprays should be available without a prescription, the overwhelming concerns expressed were about cost: 72 percent felt moving the medication OTC would increase their financial burden.

"The truth is," Sander continues, "the average patient doesn't know allergic from non-allergic rhinitis, or boggy nasal passages from sinus infections or a deviated septum. These are complex conditions, and intranasal corticosteroids are serious medications with the potential for unwanted side effects. Patients deserve the best possible care and guidance from their physicians; they should not be left on their own to self-diagnose at the pharmacy."

AANMA has identified seven important facts patients should understand regarding the efficient and safe use of intranasal corticosteroid sprays:

  1. Why the medication was prescribed
  2. How quickly to expect improvement in symptoms 
  3. What to do if symptoms don't respond as expected
  4. How to aim the nasal spray tip to deliver medication to the right part of the nose and avoid septal irritation, nose bleeds or damage
  5. How often to visit the doctor to have your nose re-examined and the treatment plan adjusted
  6. The possible role of environmental allergens and how reducing exposure at home, school, work or play could reduce symptoms
  7. The importance of a yearly eye exam and reporting all medications, including intranasal and other corticosteroids, to the ophthalmologist

Currently this information is relayed to patients by healthcare professionals, but if these medications were to be available without a prescription and patient education, the details would need to be communicated fully and clearly.

Find out more about the nasal sprays at http://www.aanma.org/2010/06/nasal-allergies-sniff-this/

ABOUT AANMA
Allergy & Asthma Network Mothers of Asthmatics (AANMA) is the leading national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions. AANMA specializes in sharing family-friendly, medically accurate information through its award-winning publications Allergy & Asthma Today magazine and The MA Report newsletter, its web site at www.aanma.org and numerous community outreach programs. Follow AANMA on Facebook at facebook.com/AANMA and on Twitter at twitter.com/AANMA.

Contact: Gary Fitzgerald
Allergy & Asthma Network
Mothers of Asthmatics
703-641-9595
gfitzgerald@aanma.org


'/>"/>
SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
2. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
3. US Intranasal Drug Delivery Industry
4. Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory Polygraphs, Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landsc
5. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
6. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
7. Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
8. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
9. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):